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Chronic Obstructive Pulmonary Disease and Work: Is It Time to Stop?
The burden of chronic obstructive pulmonary disease (COPD) and
its effect on quality of life is well known, but the effect COPD has on
work is less widely recognized. Although COPD is often thought of
as a disease of the elderly, approximately two-thirds of people with
COPD in the United States are younger than 65 years (1). Nearly
20 years ago, in a survey of 3,265 patients from nine countries in
North America and Europe, 35.7% said their condition kept them
from working, limited their ability to work, or had caused them to
have time off work in the last year (2). One third of the 447 patients
from the United States in the study reported that they were
prevented from working because of their COPD, and a further 18%
were limited in their ability to work. In a more recent survey of
nearly 2,500 patients in Brazil, China, Germany, Turkey, the
United States, and the United Kingdom aged 45–67 years, nearly
40% had retired prematurely because of COPD at an average age of
54 years (3), and numerous subsequent studies have conﬁrmed that
people with COPD are more likely to be not working (4). Some
studies have suggested that working rates fall as the severity of
airﬂow obstruction increases, but the relationship is inconsistent
(4), possibly because many patients also have comorbidities that
may be the reason for not working, rather than COPD. In some
cases, not working may reﬂect the fact that occupational exposures
worsen symptoms, and exposures can, of course, also contribute to
the development of COPD (Figure 1) (5). Workers with COPD
reported that issues leading them to stop working included work
worsening their COPD, problems getting to work, and superiors
making negative comments about their disease and not taking it
into consideration enough (6).
As well as leading to stopping working, COPD leads to
increased absenteeism (4). People with COPD are approximately
twice as likely to have a short-term disability and more than
four times as likely to have long-term disability (7), although
comorbidities may also inﬂuence this. Symptoms may also limit the
productivity of patients who remain at work. A number of large
cross-sectional studies in the United States and other countries
found that people with COPD were signiﬁcantly more likely to
report presenteeism (4), and results from studies using self-report
data indicate that approximately 13–18% are limited in what they
can do (8).
The interpretation of many of the previous studies is limited by
the fact they have mostly depended on self-reported diagnoses, have
been cross-sectional, and have generally not taken comorbidities
into account. These limitations have been overcome in the survey
reported in this issue of the Journal by Schoﬁeld and colleagues
(pp. 1228–1233), which examined the loss of employment over an
18-month-long period in patients with spirometrically conﬁrmed
airﬂow limitation (9). They found that the adjusted risk for loss
of employment was tripled for those with moderate or severe
chronic obstructive pulmonary disease (relative risk, 2.89; 95%
conﬁdence interval, 1.80–4.65), with no difference between men
and women. The risks were higher in those with worse airﬂow
obstruction or breathlessness, but were not related to comorbidities.
Patients were more likely to remain working if they had ﬁnancial
dependents.
The strengths of this study are its prospective nature; the
clinical characterization of the patients at baseline, including
postbronchodilator spirometry and assessment of comorbidities;
and the excellent response rate to the follow-up questionnaire
(93.3%). Limitations include the fact that only 33% of the eligible
population responded to the initial questionnaire, and that the
survey was performed in a single county in the United Kingdom,
perhaps affecting its generalizability. Nevertheless, the study
provides important insights into the problems faced by people
with COPD in relation to continuing working.
Working generally has a positive effect on health and
functioning. Becoming unemployed is associated with signiﬁcantly
higher levels of depression and anxiety, together with lower self-
esteem and conﬁdence (10); however, in the short term, it may lead
to improved physical health, particularly when symptoms have
been exacerbated by working conditions. The effect of COPD-
related loss of work on individuals is likely to be greatest in countries
that do not have welfare systems to support the unemployed or in
which healthcare has to be paid for. Globally, it is estimated that
384 million people had COPD in 2010 (11), with the main burden
falling in Latin America, sub-Saharan Africa, India, China, and
Southeast Asia. In many of these countries, the cost of
medication is very high in comparison to average earnings, and its
availability through government health systems is poor (12).
Without an income, these costs exacerbate the ﬁnancial vulnerability
of households in low- and middle-income countries and may
force patients to ﬁnance care by household borrowing and selling
assets (13).
Even in afﬂuent countries such as Australia, not being in paid
employment is associated with signiﬁcant economic hardship
related to the affordability of medical treatments, particularly if
patients are receiving multiple medications (14). Hardship was still
present even when patients were eligible for welfare, as this was
insufﬁcient to meet their healthcare costs in addition to daily living
expenses. Similarly, in a study of low-income seniors in the United
States, one in ﬁve did not ﬁll all their prescriptions because of cost,
and they missed doses to make their prescriptions last longer (15).
Unemployment, absenteeism, and presenteeism also have
signiﬁcant implications for national economies, both because of lost
productivity and because of the costs of beneﬁts paid to patients.
Estimates of the total indirect costs attributable to COPD vary from
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$1,521 to $3,348 for every person with COPD (8), and Sin
and colleagues estimated that among the total COPD population
in the United States there was a productivity loss of $9.9 billion
per year (16).
What can be done to maintain patients’ ability to work
and be productive for as long as possible? Maximally
reducing breathlessness and maintaining exercise capacity
with dual bronchodilator therapy in patients who are of
working age may help, as may strategies to reduce exacerbation
rates. Pulmonary rehabilitation has much to offer, but it is
essential that programs are organized in ways that are accessible
to patients who work. This might mean running sessions in
the evenings or at weekends. Workplace adjustments, such
as reducing or adjusting workload or hours and reducing
exposures to dust or irritants, may also be necessary. Such
measures can help keep patients working (6), and patients
should be encouraged to discuss them with their employers.
Maintenance of ability to work should be seen as an important
objective of COPD management. n
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Sugarcoating Lung Injury: A Novel Role for High-Molecular-Weight
Hyaluronan in Pneumonia
Despite many decades of active research and several clinical
treatment trials, acute lung injury (ALI)/acute respiratory distress
syndrome remains a severe complication of pneumonia and severe
sepsis, and pharmacological treatment is still lacking (1). The
traditional treatment of pneumonia (and infections in general) has
been to focus on the microbial component and treat patients with
antibiotics. In recent years, increased attention has been given to
the host response and ways to ameliorate the dysregulated
inﬂammatory response and tissue injury occurring after infection.
In this issue of the Journal, Liu and colleagues (pp. 1234–1245)
provide an important contribution to the literature (2) by using
translationally relevant human ALI and pneumonia models to
demonstrate the utility of high-molecular-weight hyaluronan
(HMWHA) in ALI in infection. There is increased awareness
that extracellular vesicles (EVs) play an important role in the
initiation and propagation of acute lung injury (3). The authors
demonstrate that EVs are released after the administration of
Escherichia coli in ex vivo perfused human lungs, predominantly
by endothelial cells and circulating platelets. These EVs then
promote an inﬂammatory response, leading to lung injury.
Addition of HMWHA in the perfusate after EV administration
improved alveolar ﬂuid clearance, which would decrease alveolar
edema, and decreased TNFa (tumor necrosis factor a) and IL-6
levels in the lung lavage ﬂuid. Interestingly, a decrease in
cytokine levels was noted after HMWHA treatment, even though
total white blood cell and neutrophil counts did not signiﬁcantly
change, suggesting that HMWHA reduced inﬂammatory cell
activation. Interestingly, in spite of its very large size (molecular
weight. 1,000 kD), HMWHA added in the perfusate was detected
in the alveolar after E. coli instillation. Ex vivo, HMWHA improved
bacterial clearance by phagocytes, and this was mirrored by
decreased colony-forming units in the pneumonia model.
Furthermore, HMWHA decreased EV uptake by monocytes in
a (at least partially) CD44 (cluster of differentiation 44)-dependent
manner and reduced inﬂammatory cytokine release after EV
exposure. In aggregate, these ﬁndings support that HMWHA
may be of therapeutic utility in ALI and pneumonia.
What is the relevance of these exciting ﬁndings? Hyaluronic
acid (HA) is a deceptively simple molecule present in all
extracellular matrices, consisting of repeating disaccharides made
of N-acetylglucosamine and glucuronic acid, and does not undergo
further modiﬁcation after its expression by HA synthases. Reactive
oxygen species (e.g., HOCl) released by activated inﬂammatory
cells, as well as exposures such as ozone and halogens, degrade
HMWHA to low-molecular-weight fragments (LMWHA) of
0.1–500 kD (4, 5). Although HMWHA and LMWHA bind to the
same receptors, they exert opposite effects (4). LMWHA activates
innate and adaptive immunity and increases permeability and
airway resistance by activating RhoA (ras homolog gene family,
member A) and ROCK2 (rho-associated coiled-coil containing
protein kinase 2), whereas HMWHA has strong antiinﬂammatory
and prohomeostasis functions (4). The reason for this difference
may be differences in receptor engagement or cell uptake
depending on size, but ultimately remains elusive. Recent work
suggests that HMWHA may create a transmembrane “picket
fence” barrier, tethered on CD44 and the cellular cytoskeleton,
that prevents ligands from reaching and activating their respective
receptors, an effect that as abolished after HA degradation (6).
HMWHA also binds several extracellular proteins with strong
antiinﬂammatory potential, such as inter-a-inhibitor, which is
associated with decreased endothelial injury (7) and organ
dysfunction (8, 9) in sepsis, and pentraxin-3, which contributes to
host defense, including prevention against aspergillosis in stem
cell transplant recipients (10). Furthermore, HMWHA is a
recently recognized crucial constituent of the endothelial
glycocalyx, and HA homeostasis is central to the maintenance of a
healthy endothelial barrier and the avoidance of tissue injury (11).
Finally, HA has well-described antimicrobial properties, inhibiting
bacterial adhesion and promoting phagocytosis (4). Thus, HMWHA
acts along with its binding partners in the cell, the circulation, and
the interstitium and on pathogens to reduce inﬂammation and
promote antibacterial properties of the host.
A major theoretical concern, whenever antiinﬂammatory
applications of HMWHA are being discussed, is its potential
degradation into smaller, proinﬂammatory fragments. It is
interesting to note, however, that in this study, HMWHA retained
its large molecular weight despite being several hours in a
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